Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new epilepsy drug could be on its way to FDA approval. Full phase 3 X-TOLE2 results, published in JAMA Neurology, show azetukalner slashed monthly focal seizure frequency by up to 53% compared to just 10% with placebo. The catch? The more effective 25 mg dose also brought notably more side effects, including dizziness, confusion, and a 14.5% discontinuation rate.
A promising new epilepsy drug is moving closer to FDA approval — with some important trade-offs to consider.
Full results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, show that azetukalner — a first-of-its-kind Kv7 potassium channel opener from Xenon Pharmaceuticals — significantly reduced seizure frequency in adults with drug-resistant focal epilepsy. The trial enrolled 374 patients who had already tried a median of five prior antiseizure medications, randomizing them to placebo, 15 mg, or 25 mg of azetukalner once daily over 12 weeks.
The 25 mg dose delivered the strongest efficacy but also the most side effects, setting up a classic benefit-risk balancing act for regulators and clinicians. Xenon submitted its new drug application to the FDA in September 2026, and if approved, azetukalner would be the first drug of its class available for epilepsy.
By the Numbers:
Why it matters: For patients with drug-resistant epilepsy who've exhausted most options, azetukalner represents a genuinely new mechanism of action. The dose-dependent safety profile means prescribers will need to weigh seizure control against tolerability — a conversation that will define how this drug is used if it clears FDA review.